Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Semin Arthritis Rheum. 2016 Nov 1;46(5):594–600. doi: 10.1016/j.semarthrit.2016.10.009

Table 2.

Results from the Base-Case Analysis

Lifetime Costs, $ Incremental Costs, $ QALYs QALYs Gained ICER, $/QALY
Caucasians and Hispanics (Prevalence HLA-B*5801 0.007, SJS/TEN Risk 0.00026)
No testing, initiate allopurinol-febuxostat sequential therapy $23,777 13.2248 Reference
Universal HLA-B*5801 testing $23,966 $189 13.2258 0.0010 $183,720
African Americans (Prevalence HLA-B*5801 0.038, SJS/TEN Risk 0.00136)
No testing, initiate allopurinol-febuxostat sequential therapy $23,826 13.2205 Reference
Universal HLA-B*5801 testing $24,280 $454 13.2259 0.0054 $83,450
Asians (Prevalence HLA-B*5801 0.074, SJS/TEN Risk 0.00298)
No testing, initiate allopurinol-febuxostat sequential therapy $23,898 13.2141 Reference
Universal HLA-B*5801 testing $24,648 $750 13.2257 0.0117 $64,190

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SJS, Stevens-Johnson Syndrome; TEN, Toxic Epidermal Necrolysis